Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.

Goldstein JL, Zhao SZ, Burke TA, Palmer R, von Allmen H, Henderson SC.

Am J Gastroenterol. 2003 Dec;98(12):2627-34.

PMID:
14687808
2.

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.

3.

Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

Bensen WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurath CJ, Agrawal NM, Geis GS.

J Rheumatol. 2000 Aug;27(8):1876-83.

PMID:
10955327
4.
5.

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.

8.

Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.

Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS.

Am J Gastroenterol. 2000 Jul;95(7):1681-90.

PMID:
10925968
9.

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.

PMID:
20031832
10.

Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.

J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26.

PMID:
20128070
11.

Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.

Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.

Am J Gastroenterol. 2001 Apr;96(4):1019-27.

PMID:
11316141
12.

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.

Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.

Am J Med. 2005 Nov;118(11):1271-8.

PMID:
16271912
13.

Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.

Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):366-76.

PMID:
16897817
14.

A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.

Scheiman JM, Cryer B, Kimmey MB, Rothstein RI, Riff DS, Wolfe MM.

Clin Gastroenterol Hepatol. 2004 Apr;2(4):290-5.

PMID:
15067622
15.

Underutilization of preventive strategies in patients receiving NSAIDs.

Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.

Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii23-31.

PMID:
14585915
16.

Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.

PMID:
17086567
17.

Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.

Patterson MK, Castellsague J, Walker AM.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):982-8. doi: 10.1002/pds.1639.

PMID:
18711705
18.

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.

Arch Intern Med. 2003 Feb 24;163(4):481-6.

PMID:
12588209
19.

Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs.

Niculescu L, Li C, Huang J, Mallen S.

Curr Med Res Opin. 2009 Mar;25(3):729-40. doi: 10.1185/03007990802714382 .

PMID:
19210159
20.

New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.

Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT.

Ann Pharmacother. 2007 Jun;41(6):937-43. Epub 2007 May 8.

PMID:
17488830

Supplemental Content

Support Center